trial

Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia

NCTId NCT02614586
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Terminated
Enrollment 11 (actual)
Sponsored by Takeda
Primary completion 2016-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Terminated
Enrollment
11 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2015-12
Primary completion
2016-04
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
TAK-058ondansetron

Sponsors

TakedaLead Sponsor

Sites

0 total

Facts & assertions

4 sourced
Enrollment
11
Phase
PHASE1
Primary Completion Date
2016-04
Status
TERMINATED
relationships
The graph out of here
drug
TAK-058
drug
ondansetron
drug
lead_sponsor
Takeda
company
indication
Schizophrenia
indication
Schizophrenia
indication